SCHEMBL5072295

SCHEMBL5072295

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1cc(C(=O)O)cc(C(=O)O)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
TSHR P16473 2/20 0.41
PIN1 Q13526 1/20 0.39
NPC1 O15118 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AGTR1 P30556 1/20 0.37
PPARG P37231 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NR1H3 Q13133 1/20 0.37
HDAC1 Q13547 2/20 0.36
CNR2 P34972 2/20 0.36
CNR1 P21554 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136637 0.93 C5AR1 (0.45) C5AR1TSHRPIN1NPC1SMN1; SMN2
SCHEMBL5137880 0.92 C5AR1 (0.45) C5AR1TSHRPIN1AGTR1KDM4E
SCHEMBL651094 0.89 TSHR (0.50) C5AR1TSHRSMN1; SMN2KDM4EALDH1A1
SCHEMBL649496 0.87 C5AR1 (0.44) C5AR1TSHRPIN1KDM4EALDH1A1
SCHEMBL4766671 0.86 C5AR1 (0.44) C5AR1TSHRNPC1KDM4EALDH1A1
SCHEMBL5074064 0.86 LTA4H (0.45) C5AR1TSHRPIN1AGTR1HDAC1
SCHEMBL5137576 0.86 TLR7 (0.47) C5AR1
SCHEMBL4766543 0.86 C5AR1 (0.45) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL4770661 0.86 C5AR1 (0.42) C5AR1TSHRPIN1AGTR1ALDH1A1
SCHEMBL5135922 0.85 C5AR1 (0.49) C5AR1TSHRSMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed